<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
xmlns:atom="http://www.w3.org/2005/Atom"
xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
>
<channel>
	<title>ThaiPR.NET</title>
	<atom:link href="https://www.thaipr.net/location/freiburg-germany/feed" rel="self" type="application/rss+xml" />
	<link>https://www.thaipr.net/location/freiburg-germany</link>
	<description>Press Release Distribution Center of Thailand</description>
	<lastBuildDate>Fri, 17 Apr 2026 17:23:52 +0700</lastBuildDate>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.1.1</generator>
	<item>
		<title><![CDATA[Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins]]></title>
		<link>https://www.thaipr.net/en/health_en/3108537</link>
		<dc:creator><![CDATA[thaipr.net]]></dc:creator>
		<pubDate>Tue, 12 Oct 2021 10:30:00 +0700</pubDate>
				<category>health_en</category>
		<guid isPermaLink="false">https://www.thaipr.net/en/health_en/3108537</guid>

					<description><![CDATA[<p>Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produce difficult-to-express but therapeutically promising drug candidates. Its recently expanded production capacity enables Eleva to conduct clinical studies of its [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://www.thaipr.net/en/health_en/3108537">Eleva Enters Clinical Development of Difficult-To-Express High-Potential Proteins</a> appeared first on <a rel="nofollow" href="https://www.thaipr.net">ThaiPR.NET</a>.</p>
]]></description>
									</item>
		<item>
		<title><![CDATA[Eleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member]]></title>
		<link>https://www.thaipr.net/en/health_en/3016447</link>
		<dc:creator><![CDATA[thaipr.net]]></dc:creator>
		<pubDate>Wed, 06 Jan 2021 16:15:18 +0700</pubDate>
				<category>health_en</category>
		<guid isPermaLink="false">https://www.thaipr.net/en/health_en/3016447</guid>

					<description><![CDATA[<p>Eleva, a manufacturer of superior biologics, has secured up to EUR 60 million in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one of its drug candidates, CPV-101, to stages that will facilitate further investment from venture capitalists and/or pharmaceutical companies. Eleva also announced the addition of Dr. Ralf Smit to its Executive [&#8230;]</p>
<p>The post <a rel="nofollow" href="https://www.thaipr.net/en/health_en/3016447">Eleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member</a> appeared first on <a rel="nofollow" href="https://www.thaipr.net">ThaiPR.NET</a>.</p>
]]></description>
									</item>
	</channel>
</rss>
